Entrada Therapeutics provided an update on its pipeline and financial position at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025. The company ended 2024 with approximately $420 million in preliminary unaudited cash, cash equivalents, and marketable securities, extending its cash runway into the second quarter of 2027.
Entrada anticipates having four Phase 1/2 multiple ascending dose (MAD) patient studies in Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1) by the end of 2025. This includes actively planning the initiation of two global Phase 1/2 MAD studies in the first half of 2025 and one in the second half of 2025, alongside the ongoing partnered VX-670 global Phase 1/2 MAD study.
The company highlighted positive Phase 1 data for ENTR-601-44 in DMD, which supports the initiation of a Phase 1/2 MAD clinical study in patients. This data demonstrated strong clinical safety up to 6 mg/kg, reinforcing the potential of its Endosomal Escape Vehicle (EEV) platform to address intracellular targets.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.